The resolution items referred to in the notice to the extraordinary general meeting published on 28 November 2024 at 22:30 (the English version) are as follows:

Item 11 - Resolution on reduction of share capital without withdrawal of shares for allocation to unrestricted equity (number 2).

Item 12 - Decision to a) amend the articles of association (number 2) and on b) consolidation of shares.

The board of directors intends, together with the administrator and the company's major shareholders, to continuously evaluate the need for the resolutions and whether they should be proposed again later.

Shares and share capital

The board's decision thus means that the registered share capital continues to amount to SEK 42,952,072,081.94244 divided into 9,337,409,114 shares, each share with a quota value of approximately SEK 0.0046.

For further information please contact:

Anna Linton, CEO of Peptonic Medical AB

E-mail: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About PEPTONIC medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.